Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Evaxion Biotech A/S ADR
(NQ:
EVAX
)
3.050
-0.280 (-8.41%)
Streaming Delayed Price
Updated: 3:59 PM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Evaxion Biotech A/S ADR
< Previous
1
2
Next >
Evaxion’s AI technology identifies cancer vaccine targets associated with longer progression-free survival of melanoma patients in the EVX-01 Phase 1 clinical trial
June 03, 2023
From
Evaxion Biotech
Via
GlobeNewswire
Evaxion Announces Business Update and First Quarter 2023 Financial Results
May 31, 2023
From
Evaxion Biotech
Via
GlobeNewswire
Evaxion unveils proprietary genetic adjuvant technology to boost the effect of DNA and mRNA vaccines
May 25, 2023
From
Evaxion Biotech
Via
GlobeNewswire
Evaxion announces promising clinical Phase 1 data for its personalized cancer vaccine EVX-01
May 25, 2023
From
Evaxion Biotech
Via
GlobeNewswire
Evaxion to host R&D Day on May 25, 2023
May 16, 2023
From
Evaxion Biotech
Via
GlobeNewswire
Fourth quarter and full year 2022 financial results and business update
April 27, 2023
From
Evaxion Biotech
Via
GlobeNewswire
Evaxion announces promising clinical data for DNA-based personalized cancer immunotherapy EVX-02: Phase 1/2a trial met both primary and secondary endpoints
April 18, 2023
From
Evaxion Biotech
Via
GlobeNewswire
Evaxion and Pennsylvania State University publish preclinical data validating our AI-based viral vaccine discovery platform
April 13, 2023
From
Evaxion Biotech
Via
GlobeNewswire
Evaxion Announces Increased Focus and Fast-Tracking of its New AI Discovery to Patients
March 28, 2023
From
Evaxion Biotech
Via
GlobeNewswire
Evaxion presents a new source of AI-derived immunotherapeutic targets strongly associated with the overall survival of cancer patients
March 23, 2023
From
Evaxion Biotech
Via
GlobeNewswire
Evaxion Biotech to announce clinical data for the personalized DNA cancer vaccine EVX-02 at the 2023 American Association for Cancer Research Annual Meeting (AACR)
March 14, 2023
From
Evaxion Biotech
Via
GlobeNewswire
Evaxion and Pantherna announce promising preclinical mRNA vaccine data
February 08, 2023
From
Evaxion Biotech
Via
GlobeNewswire
Evaxion receives FDA fast-track designation for personalized cancer immunotherapy
January 19, 2023
From
Evaxion Biotech
Via
GlobeNewswire
Evaxion receives approval from FDA to proceed with the clinical Phase 2b study for EVX-01
January 03, 2023
From
Evaxion Biotech
Via
GlobeNewswire
Evaxion to present a full clinical readout on two personalized cancer immunotherapies in Q2 2023
December 15, 2022
From
Evaxion Biotech
Via
GlobeNewswire
Evaxion and ExpreS²ion initiate research collaboration on a novel cytomegalovirus (CMV) vaccine candidate
December 06, 2022
From
Evaxion Biotech
Via
GlobeNewswire
Evaxion announces promising results from Phase 1/2a clinical trial of personalized DNA cancer immunotherapy EVX-02
November 17, 2022
From
Evaxion Biotech
Via
GlobeNewswire
Evaxion Announces Third Quarter 2022 Financial Results and Business Update
November 14, 2022
From
Evaxion Biotech
Via
GlobeNewswire
Evaxion CEO comments on strategic focus
November 10, 2022
From
Evaxion Biotech
Via
GlobeNewswire
Evaxion welcomes Per Norlén as new CEO.
October 05, 2022
From
Evaxion Biotech
Via
GlobeNewswire
Evaxion to Utilize Personalis’ ImmunoID NeXT Platform® to Evaluate Efficacy of Combination Therapy for Late-Stage Melanoma
April 26, 2022
From
Personalis
Via
Business Wire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.